Rubin Lab

You are here


Found 115 results
Rubin MA, Elemento O, Sboner A, Imielinski M, Pisapia D, Fernandes H, Zia H, Huang L, Tavassoli P, Kluk M.  2016.  The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretation. JAMIA.
D'Alfonso TM, Subramaniyam S, Ginter PS, Mosquera JMiguel, MacDonald TY, Noorzad Z, Orta LY, Liu Y-F, Rubin MA, Shin SJ.  2016.  Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast.. Hum Pathol.
Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JMiguel, Tomlins SA.  2016.  Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.. Mod Pathol. 29(2):157-65.
Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, rosenberg jonathan, Mosquera JMiguel, Robinson B, Elemento O et al..  2016.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.. Nat Genet. 48(12):1490-1499.
Gayvert KM, Dardenne E, Cheung C, Boland MRegina, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS et al..  2016.  A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.. Cell Rep. 15(11):2348-56.
Beltran H, Prandi D, Mosquera JMiguel, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 22(3):298-305.
Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.  2016.  DNA Repair in Prostate Cancer: Biology and Clinical Implications.. Eur Urol.
Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA.  2016.  The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.. Eur Urol.
Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.  2016.  An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.
Rubin MA, Girelli G, Demichelis F.  2016.  Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.. Eur Urol. 69(4):557-60.
Elemento O, Rubin MA.  2016.  Genomic Testing & Precision Medicine: Bigger Is Better.
Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C et al..  2016.  Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.. Sci Rep. 6:24146.
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR et al..  2016.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol.
Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S, Visakorpi T.  2016.  The Molecular Evolution of Castration-resistant Prostate Cancer. European Urology Focus.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 30(4):563-577.
Evans JR, Zhao SG, S Chang L, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA et al..  2016.  Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.. JAMA Oncol. :1-10.
Beltran H, Danila D, B M, Szmulewitz R., Vaishampayan U, Armstrong A., Stein M., Hoimes C, Pinski J., Scher H. et al..  2016.  A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).
Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA, Gerstein M.  2016.  Role of non-coding sequence variants in cancer.. Nat Rev Genet. 17(2):93-108.
Schlick B, Massoner P, Lueking A, Charoentong P, Blattner M, Schaefer G, Marquart K, Theek C, Amersdorfer P, Zielinski D et al..  2016.  Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.. PLoS One. 11(2):e0147739.